ObsEva Announces Third Quarter 2021 Financial Results and Business Update
04 nov. 2021 02h00 HE
|
ObsEva SA
-Linzagolix for uterine fibroids: Pending regulatory approval in the US and Europe with commercial planning efforts underway- -Linzagolix for endometriosis: Readout from Phase 3 EDELWEISS 3...
ObsEva Announces Management Change
29 oct. 2021 16h30 HE
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – October 29, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and...
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at ASRM 2021 Scientific Congress & Expo
20 oct. 2021 01h00 HE
|
ObsEva SA
-Final results from pilot study of linzagolix for the treatment of severe adenomyosis to be presented in a second poster - Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss...
ObsEva Announces Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at ASRM 2021 Scientific Congress & Expo
19 oct. 2021 01h00 HE
|
ObsEva SA
–Presentation of Phase 3 clinical data on linzagolix for the treatment of uterine fibroids and final results from a pilot study of linzagolix for the treatment of severe adenomyosis– GENEVA,...
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
13 oct. 2021 01h00 HE
|
ObsEva SA
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix -Linzagolix, an oral GnRH antagonist, is pending regulatory approval in the U.S. and Europe for the treatment of...
ObsEva Announces Appointment of Luigi Marro as Chief Transformation Officer
30 sept. 2021 01h00 HE
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – September 30, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and...
ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids
15 sept. 2021 01h00 HE
|
ObsEva SA
-If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options to address the clinical needs of more women with uterine fibroids- -NDA submission includes positive data...
ObsEva to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
07 sept. 2021 01h00 HE
|
ObsEva SA
GENEVA, Switzerland September 7, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today...
ObsEva Announces Second Quarter 2021 Financial Results and Business Update
05 août 2021 01h00 HE
|
ObsEva SA
-Linzagolix (Yselty®) for uterine fibroids: US New Drug Application filing planned in Q3:21; European marketing approval recommendation anticipated in Q4:21- -Linzagolix for endometriosis:...
ObsEva Announces Two Cornerstone Publications Describing Clinical Trials of Nolasiban for Improving Pregnancy and Live Birth Outcomes Following IVF
04 août 2021 01h00 HE
|
ObsEva SA
- A Combined Analysis of Pregnancy and Live Birth in more than 1800 IVF Patients Across Three Randomized, Placebo-Controlled Clinical Trials Published in the Journal of Human Reproduction- -A...